BioCentury
ARTICLE | Clinical News

Canagliflozin/metformin regulatory update

March 11, 2013 7:00 AM UTC

Johnson & Johnson's Janssen-Cilag International N.V. unit submitted an MAA to EMA for a fixed-dose combination of canagliflozin and immediate-release metformin to treat Type II diabetes in adult patients. Last December, J&J's Janssen Research & Development LLC submitted an NDA to FDA for the combination (see BioCentury, Dec. 17, 2012). ...